Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.

ABSTRACT:

Background

The RECIST-based response variably matches the clinical benefit of systemic therapies for liver metastatic uveal melanoma (LMUM). The aims were to determine whether the tumour growth rate (TGR) can help predict the survival in patients with LMUM and to provide information for the management of first-line systemic treatment.

Methods

This retrospective study included 147 (training: n = 110, validation: n = 37) patients with LMUM treated with first-line systemic treatment between 2010 and 2021. Two TGR-derived parameters were calculated, TGR₀ and TGR_3m. Multivariate Cox analyses identified independent predictors of progression-free survival (PFS) and overall survival (OS).

Results

TGR_3m was a strong independent prognostic facto

SUBMITTER: Ramtohul T 

PROVIDER: S-EPMC9296460 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature